Auspex leaps on positive results from Phase III trial of SD-809 in Huntington's chorea

17 December 2014

Movement disorder biopharma specialist Auspex Pharmaceuticals (Nasdaq: ASPX) has announced positive top-line data from its Phase III trial of SD-809, with the news causing the firm's shares to almost double to $49.82 in mid-morning trading today.

The drug was being evaluated for potential use in the treatment of chorea associated with Huntington’s disease. It met the primary efficacy endpoint and showed significant improvements in patients, while clinical global impressions of change and quality of life were observed. It also showed a positive safety and tolerability profile, causing low rates of depression, sleepiness and anxiety.

Auspex also announced results from an analysis of the completed four-week Switch portion of the study, which also has an ongoing long-term safety component. Data from the study show that patients who switched from the current standard of care, tetrabenazine, to SD-809 maintained chorea control at both week one and week four.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK